Julie R Brahmer, Georgina V Long, Omid Hamid, Edward B Garon, Roy S Herbst, Thierry Andre, Philippe Armand, Dean Bajorin, Joaquim Bellmunt, Barbara Burtness, Toni K Choueiri, Ezra E W Cohen, Luis A Diaz, Kohei Shitara, Girish Kulkarni, David McDermott, Manish Shah, Josep Tabernero, Arndt Vogel, Pier Luigi Zinzani, Niusha Jafari, Steven Bird, Ellen Snyder, Christine Gause, Oswaldo L Bracco, M Catherine Pietanza, Todd Gruber, Antoni Ribas
BACKGROUND: Pembrolizumab has a manageable safety profile as described in its label, which was primarily based on 2799 patients who participated in clinical trials for melanoma or non-small cell lung cancer. Here, we evaluated the safety of pembrolizumab in a broader population of patients from 31 advanced cancer clinical trials across 19 cancer types. METHODS: Safety was analyzed in patients who received at least one dose of pembrolizumab (200 mg every 3 weeks [Q3W], 10 mg/kg Q2W or Q3W, or 2 mg/kg Q3W)...
March 2024: European Journal of Cancer